



## PRESS RELEASE

### **Hetero launches TAFFIC, the latest 3-in-1 single pill for HIV treatment. ~The first generic Bicitegravir combination therapy in India~**

**India, Hyderabad, 17<sup>th</sup> December 2019:** Hetero, one of India's leading generic pharmaceutical companies and the world's largest producer of antiretroviral drugs, today announces the launch of the latest 3-in-1 antiretroviral combination drug under the brand name 'TAFFIC' in India. The product 'TAFFIC' is the generic version of Gilead's **Biktarvy®** and has been approved by the Drug Controller General of India (DCGI). The product will be marketed and distributed by Hetero Healthcare Ltd. in India.

**TAFFIC**, a once-a-day single pill, is a combination of three medicines - Bicitegravir (50mg), Emtricitabine (200mg), and Tenofovir Alafenamide (25mg). The product is indicated for the treatment of human immunodeficiency virus type (HIV-1) infection in adults who have no antiretroviral treatment history or replacing the current antiretroviral regimen in those who have viral copies less than 50 per ml in the blood at least for three months with no prior treatment failure and resistance to any components.

The 3-in-1 combination drug helps to prevent HIV from multiplying and works together to decrease the amount of HIV in the patient's blood to undetectable levels. This lowers the prospects of patients developing various HIV associated illnesses, thereby improving their quality of life. Studies suggest that the combination of Bicitegravir, Emtricitabine, and Tenofovir Alafenamide has shown high antiviral efficacy and safety profile in HIV patients.

TAFFIC is manufactured in Hetero's world-class manufacturing facility in Hyderabad, India, which is approved by international regulatory bodies.

Hetero is recognized as a leader in ARVs with a product portfolio of over 30 drugs and is committed to the cause of alleviating HIV/AIDS for more than two decades. The launch of this product emphasizes Hetero's ongoing commitment to provide advanced and effective treatments to HIV patients worldwide. To further this mission, Hetero will be making the latest combination drug available in 116 low and middle-income countries and is subject to approvals from the regulatory authorities in these countries.

\*\*\*\*\*

### **About Hetero**

Hetero is one of India's leading generic pharmaceutical companies and the world's largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero's strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit [www.heteroworld.com](http://www.heteroworld.com)

**Media Contact:**

Jeyasingh Balakrishnan

Head - Corporate Communications

Hetero Labs Limited

Mob: +91 9989626541/+91 9833836185